Bayer (BAYRY) Q2 Earnings Beat, Sales Miss, Cuts Guidance
Zacks Investment Research | Jul 27, 2017 01:59AM ET
Bayer AG (DE:BAYGN)’s (OTC:BAYRY) second-quarter 2017 core earnings per share from continuing operations was $1.99, which topped the Zacks Consensus Estimate of $1.87. Earnings were down 12.7% year over year from $2.28 per share.
Total sales in the quarter were approximately $13.4 billion, up 3% year over year but missed the Zacks Consensus Estimate of $14.5 billion.
Bayer’s share price has increased 25.2% year to date, outperforming the Zacks classified industry’s 10.7% rally.
All growth rates mentioned below are on a year-over-year basis and after adjusting for currency and portfolio changes.
Second-Quarter Highlights
Effective from the first quarter, Bayer reports results under five divisions – Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro.
Revenues at the Pharmaceuticals segment increased 4.4% to €4,304 million backed by a persistently strong performance of the key products Xarelto, Eylea, Xofigo, Stivarga and Adempas. Also, the company expanded its business with the hormone-releasing intrauterine devices of the Mirena product family and benefited from the launch of the new low-dose intrauterine device, Kyleena.
Moreover, Bayer recorded an increase in sales of its diabetes treatment Glucobay and its Aspirin Cardio product for the secondary prevention of heart attacks owing to the positive development of business in China.
However, Consumer Health sales were down 2.2% to €1,542 million due to declines in sales in North America, particularly in the U.S., owing to the challenging market environment. But the company expanded its business in Latin America and Europe / Middle East / Africa.
Crop Science sales were €2,163 million in the second quarter down 15.8% year over year. The decrease was due to significantly higher provisions for product returns – specifically crop-protection products – in Brazil. In fact, regular stocktaking at the end of the harvest season revealed high channel inventories in the Brazilian market, which requiries measures to be taken to normalize the situation. Notably, Bayer witnessed a decline of €428 million in sales therein. Excluding this, the Crop Science was up slightly year on year, on a currency adjusted basis.
Furthermore, sales growth recorded at Environmental Science was based on the delivery of products to the company that acquired its consumer business.
Get The News You Want
Sales of the Animal Health segment came in at €450 million, up 2.1%. In the reported quarter, sales improved positively in the regions of North America, besides progressing well in Asia Pacific region. The development in North American region was on the back of the U.S. sales generated by the Cydectin product portfolio, which the company acquired from Boehringer Ingelheim Vetmedica, Inc.
Meanwhile, Covestro garnered sales of approximately €3,479 million in the quarter, up 15.8% year over year, driven by higher selling prices especially at Polyurethanes. Volumes were at par with the year ago quarter. In fact, on Jun 7, Bayer reduced its directly held interest in Covestro from 53.3% to 44.9%, by placing 17.25 million shares at a price of €62.25 per share.
2017 Outlook
Based on the performance at Crop Science and Consumer Health, Bayer revised its outlook for 2017.
The company now expects sales to increase to more than €49 billion in 2017 compared with its previous expectation of around €51 billion. This corresponds to a mid-single-digit (previously mid- to high-single-digit) percentage increase on a currency- and portfolio-adjusted basis.
Bayer anticipated core earnings per share from continuing operations to grow by a low- to mid-single-digit percentage down from its previous expectation of mid-to high-single-digit percentage.
Our Take
Bayer surpassed earnings estimates but missed and revenue estimates in the second quarter of 2017. The company experienced a significant decline in sales and earnings in the Crop Science segment due to high channel inventories in Brazil. Business declined at Consumer Health, primarily due to the difficult market environment in the U.S.
Nevertheless, the company is looking forward to acquire Monsanto Company (NYSE:MON) in a deal worth approximately $66 billion.
Zacks Rank & Stocks to Consider
Bayer currently carries a Zacks Rank #3 (Hold). Better-ranked health care stocks in the same space include Enzo Biochem, Inc. (NYSE:ENZ) and Sanofi (NYSE:SNY) . While Enzo Biochem sports a Zacks Rank #1 (Strong Buy), Sanofi holds a Zacks Rank #2 (Buy). You can see .
Enzo Biochem’s loss per share estimates narrowed from 12 cents to 7 cents for 2017 and from 11 cents to 3 cents for 2018, over the last 30 days. The company delivered positive earnings surprises in all the trailing four quarters, with an average beat of 55.83%. The share price of the company has increased 62.7% year to date.
Sanofi’s earnings per share estimates increased from $3.18 to $3.20 for 2017 and from $3.30 to $3.36 for 2018, over last 30 days. The company pulled off positive earnings surprises in three of the trailing four quarters, with an average beat of 5.10%. The share price of the company has increased 18.7% year to date.
More Stock News: Tech Opportunity Worth $386 Billion in 2017
From driverless cars to artificial intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without.
Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future. Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential. Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.